Evolving options for the management of chronic Hepatitis B
The current management of chronic hepatitis C virus (HCV) infection almost routinely leads to sustained virologic suppression, or functional cure, and there is excitement and even expectation that a similar cure should be possible for chronic hepatitis B virus (HBV) infection. The third-generation NUCs such as entecavir (ETV) and tenofovir (TDF). Lamivudine (LMV), adefovir (ADV), and telbivudine (LdT) are no longer recommended due to their limited efficacy and moderate to high resistance rates. In the lecture Dr. N. Murugan highlight new insights and approaches for treatment of Hep B
Enroll in HCVC0020
Offered by Mylanhepatocare
Share your Case Studies
Come join our "Learn as you Teach" initiative to democratise healthcare learning by submitting your unique & interesting Case-Studies which will be reviewed by our global medical fraternity as well as an opportunity to be published in leading research journals.
Meet the Instructor
Dr. N. Murugan
Hepatologist & Liver Transplant Physician,
Apollo Hospital, Chennai, India.
Live Lecture FAQs
Firefox, Chrome, Safari and Internet Explorer
We generally encourage the use of, and fully support only, the latest version.